Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jun 8;110(12):1661-77.
doi: 10.1161/CIRCRESAHA.111.243956.

Calmodulin-dependent protein kinase II: linking heart failure and arrhythmias

Affiliations
Review

Calmodulin-dependent protein kinase II: linking heart failure and arrhythmias

Paari Dominic Swaminathan et al. Circ Res. .

Abstract

Understanding relationships between heart failure and arrhythmias, important causes of suffering and sudden death, remains an unmet goal for biomedical researchers and physicians. Evidence assembled over the past decade supports a view that activation of the multifunctional Ca(2+) and calmodulin-dependent protein kinase II (CaMKII) favors myocardial dysfunction and cell membrane electrical instability. CaMKII activation follows increases in intracellular Ca(2+) or oxidation, upstream signals with the capacity to transition CaMKII into a Ca(2+) and calmodulin-independent constitutively active enzyme. Constitutively active CaMKII appears poised to participate in disease pathways by catalyzing the phosphorylation of classes of protein targets important for excitation-contraction coupling and cell survival, including ion channels and Ca(2+) homeostatic proteins, and transcription factors that drive hypertrophic and inflammatory gene expression. This rich diversity of downstream targets helps to explain the potential for CaMKII to simultaneously affect mechanical and electrical properties of heart muscle cells. Proof-of-concept studies from a growing number of investigators show that CaMKII inhibition is beneficial for improving myocardial performance and for reducing arrhythmias. We review the molecular physiology of CaMKII and discuss CaMKII actions at key cellular targets and results of animal models of myocardial hypertrophy, dysfunction, and arrhythmias that suggest CaMKII inhibition may benefit myocardial function while reducing arrhythmias.

PubMed Disclaimer

Figures

Figure 1
Figure 1. CaMKII becomes constitutively active by autophosphorylation and/or oxidation and constitutively active CaMKII promotes core events important for heart failure and arrhythmias
The CaMKII holoenzyme consists of two hexameric stacked rings. Under resting conditions the catalytic subunit is conformationally constrained so that CaMKII is inactive (top). CaMKII is initially activated when Ca2+ bound calmodulin (Ca2+/CaM, dumbbell shapes) bind to the regulatory domain (blue segments) causing a more extended conformation where the catalytic domain (green) becomes accessible to substrate proteins and ATP. Sustained increases in Ca2+ lead to autophosphorylation at Thr 287, enhancing the avidity of CaM binding but also inducing a Ca2+/CaM-independent form of CaMKII after CaM unbinding. Oxidation of Met 281/282 induces a Ca2+/CaM-independent form of CaMKII without CaM trapping. Increased levels of autophosphorylated or oxidized CaMKII favor heart failure and arrhythmias, at least in part, by activating hypertrophic and inflammatory gene programs, inducing proarrhythmic electrical remodeling, increasing myocyte death and fibrosis and defective intracellular Ca2+ homeostasis.
Figure 2
Figure 2. The domain structure of a CaMKII monomer
Each CaMKII monomer has a C terminus association domain and an N terminus catalytic domain. The internal regulatory domain consists of a C terminal side Ca2+/CaM binding region (CaM-B) and an N terminal side autoinhibitory region (AI). Oxidation at Met 281/282 or autophosphorylation at Thr 287 prevent reassociation of the catalytic domain and the AI sequence, leading to constitutive, Ca2+/CaM-independent CaMKII activity.
Figure 3
Figure 3. Myocardial cell ultrastructure creates close associations between CaMKII targets important for membrane excitability and intracellular Ca2+ homeostasis
Activated CaMKII enhances cellular Ca2+ entry by catalyzing phosphorylation of voltage-gated Ca2+ channels (mostly CaV1.2 in ventricle) and ryanodine receptor (RyR2) Ca2+ release channels. CaV1.2 and RyR2 are brought into close association (~10 nm) by CaV1.2 enrichment on T-tubular sarcolemmal invaginations. CaMKII phosphorylation of voltage-gated Na+ channels (mostly NaV1.5 in ventricle) increases subsarcolemmal Na+ concentration that disadvantages the electrochemical driving force for Ca2+ extrusion from the cell by the Na+/Ca2+ exchanger (NCX), leading to increased intracellular Ca2+ concentration.
Figure 4
Figure 4. CaMKII anchoring at CaV1.2 and NaV1.5
CaMKII associates with two important voltage-gated ion channels by catalytic domain binding to a recognition sequence that resembles the autoinhibitory region of the CaMKII regulatory domain. A sequence conserved across validated CaMKII targets is present on the β subunit of CaV1.2 (bottom panel) and on βIV spectrin, a cytoskeletal protein associated with Ankyrin G and the NaV1.5 (top panel). These sequences are required for CaMKII to regulate CaV1.2 and NaV1.5 currents.
Figure 5
Figure 5. Oxidized CaMKII leads to SA node cell death and SA node dysfunction
Under physiological conditions (top) the SA node initiates each heart beat by inducing an inward current of sufficient magnitude to depolarize surrounding atrial myocardium with high fidelity. Activation of NADPH oxidase by angiotensin II leads to CaMKII activation by oxidation and excessive oxidized CaMKII leads to SA node cell apoptosis. SA node dysfunction occurs when SA node cell loss beyond a critical threshold prevents high fidelity capture of surrounding myocardium (bottom).

Similar articles

Cited by

References

    1. Schocken DD, Benjamin EJ, Fonarow GC, Krumholz HM, Levy D, Mensah GA, Narula J, Shor ES, Young JB, Hong Y Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. American Heart Association Council on Epidemiology and Prevention, American Heart Association Council on Clinical Cardiology, American Heart Association Council on Cardiovascular Nursing, American Heart Association Council on High Blood Pressure Research, Quality of Care Outcomes Research Interdisciplinary Working Group, Functional Genomics and Translational Biology Interdisciplinary Working Group. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research. Circulation. 2008;117(19):2544–2565. - PubMed
    1. Members WG, Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J Executive Summary: Heart Disease and Stroke Statistics--2011 Update: A Report From the American Heart Association. Committee OBOTAHAS Subcommittee SS Roger VL Turner MB Disease OBOTAHAH Group SSW. Circulation. 2011;123(4):459–463. - PMC - PubMed
    1. Lloyd-Jones D, Adams R, Brown T, Carnethon M. Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation. 2010 - PubMed
    1. Krell MJ, Kline EM, Bates ER, Hodgson JM, Dilworth LR, Laufer N, Vogel RA, Pitt B. Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. Am. Heart J. 1986;112(4):787–791. - PubMed
    1. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N. Engl. J. Med. 1991;324(12):781–788. - PubMed

Publication types

MeSH terms

Substances